Blog

INDIANAPOLIS, INDIANA / ACCESS Newswire / October 20, 2025 / Arrive AI (NASDAQ:ARAI), an autonomous delivery network anchored by patented AI-powered Arrive Points™, today announced its inclusion in the Russell 2000® and the Russell 3000® Indexes.

“Arrive AI’s addition to the Russell 2000® and 3000® Indexes elevates our visibility within the broader institutional investment community and showcases our positively disruptive strategy to revolutionize last mile delivery with smart mailboxes and a Mailbox-as-a-Service, or MaaS, platform,” said Arrive AI Founder and CEO Dan O’Toole. “It also enhances our credibility and widens participation across the investing spectrum. This is a huge, galvanizing milestone that validates everything that we have worked for and that we continue to reach for every, single day. This means that Arrive AI is one of the 3,000 largest publicly traded companies, and that is gratifying beyond words.”

The Russell Indexes are among the most widely used benchmarks for U.S. small-cap equities by the investment community, spanning diverse asset classes and investment objectives. Inclusion opens access to a broad base of institutional investors, index funds and ETFs that track these benchmarks, supporting increased liquidity and long-term shareholder value.

ARAI’s ranking is based on the company’s market capitalization, financial performance and growth trajectory.

-30-

About Arrive AI

Arrive AI’s patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox, whether by drone, ground robot or human courier. The platform provides real-time tracking, smart logistics alerts and advanced chain of custody controls to support shippers, delivery services and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting and security systems to streamline the entire last-mile delivery experience. Learn more at www.arriveai.com and the company’s press kit. Media contact: Cheryl Reed, media@arriveai.com Investor Relations Contact: Alliance Advisors IR, ARAI.IR@allianceadvisors.com

Cautionary Note Regarding Forward Looking Statements

This news release and statements of Arrive AI’s management in connection with this news release or related events contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “considers”, “intends”, “plans”, “prepares”, “believes”, “potential”, “will”, “should”, “could”, “would”, “wants”, “optimistic”, “in the process of” or “may” and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results, and involve significant known and unknown risks, uncertainties and other factors which may be beyond our control. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. Potential investors should review Arrive AI’s Registration Statement and other filings with the Securities Exchange Commission, for more complete information, including the risk factors that may affect future results, which are available for review at www.sec.gov. Accordingly, forward-looking statements should not be relied upon as predictors of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

SOURCE: Arrive AI Inc.

View the original press release on ACCESS Newswire

Former UBS executive and Wealthspire Trust CEO will guide the firm’s growth and operations, reinforcing its position as America’s premier advisor-friendly corporate trustee.

RAPID CITY, SD / ACCESS Newswire / October 20, 2025 / Wealth Advisors Trust Company (WATC), a leading advisor-friendly corporate trustee, today announced the appointment of Jonathan Connolly as President and Chief Operating Officer (COO). Connolly brings more than 30 years of leadership in fiduciary and wealth management to guide WATC’s strategic growth, brand evolution, and expansion into new markets.

Throughout his career, Connolly has held senior roles at UBS AG, Comerica Bank & Trust, RBC Trust Company of Delaware, PNC Bank, and TD Bank. Most recently, he served as CEO and President of Wealthspire Trust LLC, a Tennessee-chartered public trust company. Connolly is known for building fiduciary platforms that serve ultra-high-net-worth families, family offices, and institutional partners, always with an emphasis on collaboration, innovation, and client-centric administration.

“Wealth Advisors Trust Company was founded on the belief that trustees should simplify relationships, not complicate them,” said Jonathan Connolly, President & COO, WATC. “Together, we’re redefining what partnership means in fiduciary service-being kind, responsive, and collaborative while empowering advisors and attorneys to deliver exceptional outcomes for their clients. As we expand nationally, WATC remains committed to protecting legacies with the same compassion, precision, and integrity that has defined our success.”

Founded in 2009 by advisors seeking a better way to serve clients, WATC was built by advisors, for advisors as an independent, custodian-agnostic trust company grounded in South Dakota’s robust fiduciary framework. Under Connolly’s leadership, WATC now enters a new chapter of transformation and growth within the U.S. market, anchored by its enduring promise-because You expect more.

“At Wealth Advisors Trust Company, our goal has always been to make advisors more competitive by helping them retain and grow trust assets,” said Christopher Holtby, Co-Founder of WATC. “Jonathan brings a deep understanding of how fiduciary partnerships drive advisor growth. His leadership will accelerate our expansion and deepen the value we provide to advisors and attorneys nationwide.”

WATC currently oversees $4 billion in assets under administration and serves more than 400 trust relationships nationwide. As an independent, non-competitive fiduciary, WATC enables advisors and attorneys to remain central to their client relationships while delivering operational excellence behind the scenes.

Under Connolly’s direction, WATC’s expansion will continue into the Mid-South, New England, and key West Coast markets offering collaborative, compassionate trust services to more advisors, attorneys, and families seeking an effective and highly-reputable fiduciary partner.

SOURCE: Wealth Advisors Trust Company

View the original press release on ACCESS Newswire

Open-access publication demonstrates the validity and reliability of the Mentavi online Diagnostic Evaluation compared to a clinical interview, widening evidence based telehealth access for adults with ADHD.

GRAND RAPIDS, MICHIGAN / ACCESS Newswire / October 20, 2025 / Mentavi Health announced that its landmark, real-world validation study of the Mentavi Diagnostic Evaluation has been published in the peer reviewed Journal of Clinical Psychiatry (JCP). In what is believed to be the first peer-reviewed study of its kind, an asynchronous, online evaluation matched the diagnostic accuracy of a clinician-led interview for adult ADHD. This publication provides the first peer-reviewed evidence base for a fully digital diagnostic pathway for adult ADHD.

Primary endpoints and results

• n = 345 adults seeking web based ADHD assessment (predominantly female; mean age = 35).

• Sensitivity = 80.6% and Positive Predictive Value = 94.9%.

• False positive rate = 12% versus 56% for the clinical interview, indicating the online tool is accurate in diagnosing ADHD in adults.

• Note: the full article is freely available via the Journal of Clinical Psychiatry (DOI below).

Why it matters

The findings address concerns about rigor in digital diagnostics by showing that an asynchronous, clinician reviewed online pathway can perform comparably on key performance metrics to a structured face-to-face clinical interview conducted via video-while being more conservative in assigning ADHD negative diagnoses.

Study design

The prospective, real-world observational study compared the Mentavi Diagnostic Evaluation-a self-paced, asynchronous questionnaire interpreted by a doctorate level psychologist-with a structured face-to-face clinical interview conducted via video. Primary endpoints were sensitivity, specificity, and positive predictive value relative to DSM5 criteria. The protocol was IRB approved and powered to detect ≥80% sensitivity with 95% confidence.

Clinical and public health implications

• Pent up demand: an estimated 17 million American adults have ADHD, yet waiting lists for specialist evaluation can exceed six months.

• Telehealth preference: CDC data indicate 46% of U.S. adults with ADHD already use telehealth services. Until now, no online assessment had been validated.

• Health equity impact: Digital, asynchronous tools remove geographic and scheduling barriers, enabling evidence based diagnosis for rural, underserved, and shift working populations. 

Executive comments

“Publication in a top-tier peer-review journal moves this evidence base forward, for our diagnostic evaluation specifically and for telehealth in general,” said Barry K. Herman, MD, MMM, chief medical officer at Mentavi Health and first author of the paper. “The study shows that an online ADHD diagnosis can be accurately assessed asynchronously, closing gaps in care created by specialist shortages and long waitlists.”

Andrew J. Cutler, MD, chief medical officer at the Neuroscience Education Institute, clinical associate professor of psychiatry at SUNY Upstate Medical University, and study co-author, commented: “As one of the first large peer-reviewed evaluations of a telehealth ADHD tool, this paper will shape guidelines and payer policies worldwide.”

“Publication in the JCP sets a new standard for evidence-based digital mental health,” added Keith Brophy, CEO of Mentavi Health. “It validates years of work to build a rigorous online diagnostic platform and expands our mission to remove barriers of access to accurate mental-health assessments.”

Where to learn more

• Peer-reviewed validation study, open access: The Journal of Clinical Psychiatry

• Article title: Validity of an Online Assessment of Attention Deficit/Hyperactivity Disorder Among a RealWorld Sample of Adults Seeking Web Based Mental Health Care (open access)

• Byline: Barry K. Herman, MD, MMM; Stephen V. Faraone, PhD; Andrew J. Cutler, MD; Jeffrey H. Newcorn, MD; Emily M. LaFrance, PhD; Michelle Ripper Lewis, BSN, RN; Charles Ruetsch, PhD

• Citation: J Clin Psychiatry. 2025;86(3):25m15846

• DOI: 10.4088/JCP.25m15846

About Mentavi Health and ADHD Online

Established as ADHD Online in 2018, Mentavi Health has evolved to encompass a broader range of mental health services. With the mission to make high-quality ADHD assessments accessible to all, Mentavi has grown to address not only ADHD but also the most common related mental health conditions. The nationwide Mentavi Mental Health Diagnostic Evaluation and various treatment options showcase the company’s commitment to providing comprehensive, accessible, compliant online mental health care. For more information, visit mentavi.com.

Contact Information

Tim Cox
ZingPR for Mentavi
tim@zingpr.com

Related Video

https://www.youtube.com/watch?v=N6Xd9UJRO9s

SOURCE: Mentavi Health

Related Images

View the original press release on ACCESS Newswire

Collaboration creates a valuable content portfolio for sponsors, broadcasters and digital publishers looking to get a headstart on the stories shaping next year’s biggest sporting event in history

MONACO, MC / ACCESS Newswire / October 20, 2025 / SEVN Worldwide, the media rights and distribution agency, today announced it has secured exclusive live broadcast, VOD, digital syndication, and in-stadium media activation rights for the Monterrey Legends Match, taking place January 17, 2026 at Estadio Monterrey, home of Liga MX including the Rayadas & Rayados.

The collaboration marks the first live football event that will highlight legends of the game who have excelled representing their club and national teams. In September 2024, Monterrey became the first host city to stage a Legends Match, when global icons including Carles Puyol, Andrea Pirlo, John Terry and Didier Drogba took to the pitch. SEVN Worldwide served as the media rights agency of record for this global football event that was widely praised and recognized for its production value, reach, and innovation.

Broadcast production and distribution of the prior Legends Match at Estadio Monterrey was led by Televisa via TUDN and VIX and amplified throughout Mexico, United States, and globally by major broadcasters including Multimedios, BEIN Sports, Fox Deportes, Directv Latin America, and FIFA+. Through partnerships with Meta and Twitch, SEVN bridged generations of football fandom, bringing the legends of the game to life for digital-native audiences who’ve learned about them through family heritage, streaming culture, and the global popularity of EA FC.

“This rights package integrates exclusive live and VOD content with dynamic pre- and post-match programming, creating a powerful platform for partners to engage fans at scale and collect meaningful first-party insights,” said Greg Bobolo, Founder & CEO, SEVN. “Inside the venue, we’re extending that experience, offering new ways for fans and sponsors to connect across every device.”

“Partnering with SEVN allows us to deliver the Legends Match to fans worldwide with cutting-edge distribution and sponsor experiences that match the excitement on the field,” said Alejandro Hütt, Host City Manager Monterrey. “Their proven performance and forward-thinking use of AI and new technologies continue to expand the commercial and fan value of our intellectual property.”

As anticipation builds toward 2026, inventory of premium football content of this caliber remains extremely limited and in exceptionally high demand. Following the tremendous success of last year’s Legends Match, which drew more than 35,000 fans to Estadio Monterrey and achieved standout viewership across multiple broadcast and streaming platforms, SEVN and Host City Monterrey are already fielding strong interest from networks throughout North America and beyond. The renewed rights package positions Monterrey as a key gateway for global broadcasters, brands, and digital publishers eager to capture the energy of the world’s most anticipated sporting event before it kicks off.

SEVN is currently engaging global distribution and regional sponsorship partners seeking to connect with football audiences ahead of the largest global sporting event in history. Founder & CEO Greg Bobolo and Managing Partner JB John-Baptiste will be available for press and partner briefings October 19-22 at SPORTEL Monaco.

About SEVN Worldwide

SEVN Worldwide is a media rights and distribution agency that maximizes the value of sports and entertainment content through strategic syndication, short-form packaging, and integrated sponsorships.

About the Monterrey Host Committee for the FIFA World Cup™ 2026

The Monterrey Host Committee is responsible for organizing and delivering world-class experiences as part of the FIFA World Cup 2026™. Its legacy program is designed to leave a lasting social, cultural, and health impact on local and global communities.

###

Media Contact:

Julie Mathis
310-428-5305
Julie.Mathis@TheCrooksGroup.com

SOURCE: SEVN Worldwide

View the original press release on ACCESS Newswire

CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. The details of the presentations are as follows:

• Late-Breaking Oral Presentation #229: mRNA-1010, an mRNA-Based Influenza Vaccine, is Safe and Efficacious in Adults Aged ≥50 Years: The presented data show the relative vaccine efficacy (rVE) of mRNA-1010 for the prevention of influenza compared to a licensed standard dose (SD) influenza vaccine. rVE was 26.6% (95%CI: 16.7%, 35.4%) in the overall study population, meeting the prespecified superiority criteria. rVE was consistent across vaccine-included strains, including Influenza B strains. mRNA-1010 also protected against more severe, including medically-attended influenza, with an rVE of 33.7% (95%CI: 12.0, 50.0%) compared to a licensed SD influenza vaccine. mRNA-1010 was well-tolerated, with no safety concerns identified. Injection site pain was the most common local solicited adverse reactions (SARs), and fatigue, headache and myalgia were the most common systemic SARs reported.

  • Presenter: Eleanor Wilson, MD, MHS

  • Time: Monday, October 20, 3:15-4:30pm ET

  • Location: B401-B402

• Oral Presentation #220: Safety and Immunogenicity of mRNA-1018, a candidate vaccine for the prevention of H5N1 pandemic influenza, in healthy adults ≥18 years of age in a dose-ranging Phase 1/2 clinical study: The presented data show that across all dose levels, mRNA-1018 was well-tolerated with no safety concerns identified, and demonstrated rapid and persistent immune response. Three weeks after the second dose, the immune responses in 97.8% of participants (95%CI: 95.4, 99.2) were at or above levels considered protective from influenza. Notably, as soon as three weeks after the first dose, immune responses at or above the accepted threshold for protection were observed in 79.5% (95%CI: 74.3, 84.1) of participants and six months after the second dose, 70.6% (95%CI: 64.8, 76.0) maintained seroprotective titers.

  • Presenter: Brett Leav, MD

  • Time: Monday, October 20, 3:15-4:30pm ET

  • Location: B207-B208

Moderna will also present the following:

• Oral Presentation #90: Interim Assessment of Safety and Immunogenicity from a Proof-of-Concept Phase 2 Trial of an mRNA-Based Cytomegalovirus Vaccine in Patients Who Have Undergone Allogeneic Hematopoietic Cell Transplantation

  • Presenter: Lori Panther, MD, MPH

  • Time: Monday, October 20, 10:30-11:45am ET

  • Location: B211-B212

• Oral Presentation #223: Safety, Tolerability, and Immunogenicity of the mRNA-1345 RSV Vaccine in Solid Organ Transplant Recipients Aged ≥18 Years

  • Presenter: Eric F. Mayer, MD

  • Time: Monday, October 20, 3:15-4:30pm ET

  • Location: B207-B208

• Late-Breaking Oral Presentation #407: Cardiac Troponin I Levels Following mRNA-1273 Vaccination in Participants 12 Through 30 Years of Age: Results from a Phase 4 Randomized, Placebo-Controlled Study

  • Presenter: Spyros Chalkias, MD

  • Time: Tuesday, October 21, 1:45-3:00pm ET

  • Location: B401-B402

• Oral Presentation #563: Safety and Immunogenicity of mRNA-1273.815 in COVID-19 Vaccine-Naïve Children 2 Through 4 Years of Age: Results from a Phase 3, Open-Label Trial

  • Presenter: Avika Dixit, MBBS

  • Time: Wednesday, October 22, 10:30-11:45am ET

  • Location: B207-B208

• Oral Presentation #642: mRNA-1608, an mRNA-Based Therapeutic Genital Herpes Vaccine Candidate: Interim Safety, Immunogenicity and Clinical Endpoint Results from a Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Trial

  • Presenter: Anna Wald, MD, MPH

  • Time: Wednesday, October 22, 1:45-3:00pm ET

  • Location: B211-B212

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including pioneering work on COVID-19 vaccines.


Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy, safety and tolerability of Moderna’s product candidates. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:

Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:

Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

Hartgraves & the Adventure in Time!

FORT WORTH, TX / ACCESS Newswire / October 19, 2025 / Author Pete Hartgraves is captivating young readers and educators alike with his debut novel, Adventures in Time: My Only Regret – the first book in a thrilling new historical fiction series for middle-grade and young adult readers. The story blends adventure, friendship, and time travel with real moments from America’s past, creating a fresh and engaging way for students to experience history.

Adventures in Time: My Only Regret follows three friends – Billy, Joanne, and Bobby – who accidentally activate their science teacher’s experimental time-displacement device and are transported into the era of the American Revolution. As they navigate divided loyalties, questions of freedom, and the challenges of a world far removed from their own, the trio must rely on courage, critical thinking, and each other to find their way home.

Hartgraves, who writes from Fort Worth, Texas, says his inspiration comes from a desire to make history meaningful for young readers:

“I write children’s fiction and historical fiction for young adults. My goal is to give young readers stories that are both exciting and meaningful – adventures that teach without ever feeling like lessons.”

Teachers, parents, and students in grades 5 through 9 have praised the book for its mix of accurate historical context and relatable storytelling. The novel’s humor, emotional depth, and fast-moving plot make it an ideal classroom companion for educators seeking to bring history alive.

Building on the success of the first book, Hartgraves has announced that the second installment in the series, Adventures in Time: Destination 2 – The Underground Railroad, is soon to be released. This next adventure will take readers deep into one of America’s most courageous chapters, where friendship and bravery are tested against the backdrop of the fight for freedom.

“The story is historical with lots of adventure,” Hartgraves says. “It’s an exciting book for a group that doesn’t receive much in the area of good literature.”

The Adventures in Time Series by Pete Hartgraves

About the Author

Pete Hartgraves writes historical fiction and adventure stories for children and young adults. His work combines imagination with educational depth, helping readers connect with history in a personal and meaningful way. Hartgraves lives south of Fort Worth, Texas, where he continues to write stories that encourage curiosity, empathy, and lifelong learning.

Check Google Books for availability and upcoming titles in the Adventures in Time series.

Disclaimer

This release was prepared by the author & trh editorial team at Evrima Chicago, a media, technology, and communications company specializing in assistive technology innovation, digital publishing, and independent press representation. The views and statements expressed herein are those of the author and do not necessarily reflect the views of Evrima Chicago or its affiliates.

Evrima Chicago constructs its editorial materials based on publicly available information, direct author communication, and verifiable publishing data. While every effort has been made to ensure factual accuracy and fair representation, readers are encouraged to consult original sources, such as the publisher’s and author’s official listings, for updates or corrections.

For interview requests, syndication inquiries, or press credentials,

Media Contact

Dan Wasserman
Team PR | Evrima Chicago
PR@EvrimaChicago.com

For editorial & technical concerns, Waasay@evrimachicago.com

SOURCE: Evrima Chicago LLC.

View the original press release on ACCESS Newswire